{"id":28169,"date":"2026-02-19T14:29:46","date_gmt":"2026-02-19T14:29:46","guid":{"rendered":"https:\/\/www.medicalbillersandcoders.com\/blog\/?p=28169"},"modified":"2026-05-19T16:18:40","modified_gmt":"2026-05-19T10:48:40","slug":"dry-eye-disease-billing-cpt-codes","status":"publish","type":"post","link":"https:\/\/www.medicalbillersandcoders.com\/blog\/dry-eye-disease-billing-cpt-codes\/","title":{"rendered":"Which Dry Eye Disease Billing CPT Codes Maximize Your Optometry Revenue in 2026?"},"content":{"rendered":"

The dry eye disease billing CPT codes that maximize optometry revenue in 2026 are 83861<\/strong> (tear osmolarity, ~$44.96 bilateral), 68761<\/strong> (punctal occlusion, now capped at 6 lifetime plugs under VSP), G2211<\/strong> (longitudinal complexity add-on for E\/M visits), and 0207T<\/strong> for automated MGD evacuation \u2014 each requiring specific modifier strategies and documentation protocols to survive payer scrutiny and protect your Net Collection Ratio.<\/p>\r\n

Dry eye disease is no longer a minor inconvenience code on your superbill. It is a chronic, medically necessary condition generating high-frequency encounters, procedure revenue, and diagnostic reimbursement \u2014 but only when your dry eye disease billing CPT codes are matched to the right modifiers, documentation, and 2026 payer rules. Get this wrong and you are not just leaving revenue on the table; you are inviting recoupment.<\/p>\r\n

Managing dry eye disease billing CPT codes across multiple payers, modifier rules, and Category III tracking is not a task your front-desk billing staff can absorb alongside routine claim submission \u2014 it requires dedicated specialty infrastructure.<\/p>\r\n

Here is the 2026 code-by-code breakdown every optometry practice needs before submitting another DED claim.<\/p>\r\n

The 2026 Regulatory Backdrop Every Practice Must Understand First<\/h2>\r\n

The CMS 2026 Medicare Physician Fee Schedule final rule (Federal Register, November 2025) set the conversion factor at $33.4009<\/strong> \u2014 a 3.26% increase from 2025. However, the increase is not uniform. Office-based procedures see modest gains, while ASC and facility-based services face efficiency-driven cuts.<\/p>\r\n

For dry eye disease billing specifically, this means site-of-service selection directly impacts your margin on procedural codes like 68761 and 0207T.\u00a0Practices relying on general medical billing services unfamiliar with the 2026 fee schedule dynamics risk systematic underpayment on their highest-volume DED encounters.<\/p>\r\n

You can verify all 2026 payment rates directly via the official CMS Physician Fee Schedule Search tool<\/a>.<\/p>\r\n

Core Dry Eye Disease Billing CPT Codes: 2026 Code-by-Code Breakdown<\/h2>\r\n

CPT 83861 \u2014 Tear Osmolarity Testing<\/h3>\r\n

This microfluidic analysis is reimbursed under the CMS Clinical Laboratory Fee Schedule at approximately $22.48 per eye<\/strong> ($44.96 bilateral). It is one of the few DED diagnostics with consistent Medicare Part B coverage \u2014 but only when billed correctly. Required modifiers: QW<\/strong> (CLIA-waived), LT<\/strong> (left eye), RT<\/strong> (right eye). Bill as one unit per eye per line. No patient copayment or deductible applies when billed under the Lab Fee Schedule.<\/p>\r\n

Billing Alert:<\/strong> Submitting 83861 without the QW modifier is one of the top five dry eye disease billing CPT code errors flagged in payer audits. Verify your EHR default billing profile includes QW before batch submission.<\/p>\r\n

CPT 68761 \u2014 Punctal Occlusion<\/h3>\r\n

A major policy update from VSP Vision Care, effective February 1, 2026<\/strong>, reshaped how practices bill punctal plugs. Providers may now file CPT 68761 for a maximum of six punctal plugs per patient lifetime<\/strong> \u2014 any combination of temporary or permanent \u2014 and the “SC” modifier is no longer required for temporary plugs under Essential Medical Eye Care. Practices still billing with the SC modifier on temporary plugs are generating clean-claim failures that delay payment by 14\u201321 days on average.<\/p>\r\n

CPT 0207T \u2014 Automated MGD Evacuation (LipiFlow, TearCare)<\/h3>\r\n

This Category III code covers thermal pulsation therapy. Medicare coverage remains inconsistent across contractors. Before performing the procedure, practices must issue a signed Advance Beneficiary Notice (ABN)<\/strong> \u2014 a non-negotiable compliance step governed by CMS ABN policy<\/a>.<\/p>\r\n

Failure to obtain a signed ABN before service eliminates your ability to bill the patient if Medicare denies the claim. Tracking Category III codes for future coverage expansion is a long-term revenue strategy your billing infrastructure must support.<\/p>\r\n

G2211 \u2014 Longitudinal Complexity Add-On<\/h3>\r\n

This is the most underutilized revenue tool in the DED billing toolkit. G2211 compensates providers for “visit complexity inherent to a longitudinal relationship” \u2014 exactly what chronic DED management represents. It appends to E\/M codes 99202\u201399215<\/strong> when you serve as the continuing focal point for a patient’s DED care.<\/p>\r\n

Critical restriction:<\/strong> G2211 cannot be billed with 92xxx eye codes<\/strong> or when modifier -25<\/strong> is used on the same claim for most services. Switching from 92012\/92014 to 99xxx E\/M coding for appropriate chronic DED encounters unlocks G2211 and adds measurable per-encounter revenue.<\/p>\r\n

2026 Dry Eye Disease CPT Code Quick-Reference Table<\/h2>\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n
CPT Code<\/strong><\/td>\r\nService<\/strong><\/td>\r\n2026 Reimbursement \/ Coverage<\/strong><\/td>\r\nCritical Compliance Rule<\/strong><\/td>\r\n<\/tr>\r\n<\/thead>\r\n
83861<\/td>\r\nTear Osmolarity<\/td>\r\n~$22.48\/eye; $44.96 bilateral (Lab Fee Schedule)<\/td>\r\nQW + LT\/RT modifiers required; no copay\/deductible<\/td>\r\n<\/tr>\r\n
68761<\/td>\r\nPunctal Occlusion<\/td>\r\nVaries by payer; VSP: 6 plugs\/lifetime max (eff. Feb 1, 2026)<\/td>\r\nSC modifier no longer required for temporary plugs (VSP)<\/td>\r\n<\/tr>\r\n
0207T<\/td>\r\nMGD Evacuation (Automated)<\/td>\r\nCategory III; limited Medicare contractor coverage<\/td>\r\nSigned ABN mandatory before service delivery<\/td>\r\n<\/tr>\r\n
G2211<\/td>\r\nLongitudinal Complexity Add-On<\/td>\r\nAdd-on to 99202\u201399215; not separately payable in all plans<\/td>\r\nCannot bill with 92xxx codes or modifier -25 in most cases<\/td>\r\n<\/tr>\r\n
92285<\/td>\r\nExternal Ocular Photography<\/td>\r\nCovered when medically necessary (MGD documentation)<\/td>\r\nInterpretation + report must be in chart<\/td>\r\n<\/tr>\r\n
0507T \/ 0330T<\/td>\r\nMeibography \/ Tear Film Imaging<\/td>\r\nCategory III; payer-specific coverage<\/td>\r\nDocument clinical rationale; track for coverage expansion<\/td>\r\n<\/tr>\r\n<\/tbody>\r\n<\/table>\r\n

Sources: CMS Physician Fee Schedule Search Tool (cms.gov) | Medicare NCCI Edits<\/em><\/p>\r\n

2026 dry eye billing: top denial patterns by payer<\/h2>\r\n

Knowing the codes is necessary but not sufficient. The practices that protect their dry eye NCR in 2026 are the ones that know which payer denies which code for which reason<\/em> \u2014 and have the documentation to preempt it. Here are the four denial patterns MBC sees most frequently across optometry clients billing DED:<\/p>\r\n

    \r\n
  • 83861 denied by commercial payers as “not medically necessary”<\/strong> \u2014 most commonly from UnitedHealthcare and Cigna, which require a minimum of 6 weeks of documented artificial tear use before approving osmolarity testing. Practices submitting 83861 on a first DED visit without prior conservative therapy notation in the chart trigger automatic medical necessity denials that are rarely worth the appeal cost.<\/li>\r\n
  • 68761 denied under frequency limits<\/strong> \u2014 commercial payers increasingly apply per-visit or per-year plug limits that differ from VSP’s lifetime cap. Humana, for example, applies a 4-plug-per-year frequency edit in many markets. Without pre-authorization or eligibility verification that surfaces the plan-specific limit, the claim pays initially then recoups on audit.<\/li>\r\n
  • 0207T denied for missing ABN<\/strong> \u2014 the single most common compliance failure for practices offering LipiFlow or TearCare. The ABN must be signed before the procedure is performed, not at checkout. Post-procedure ABN collection has no legal standing under CMS policy and leaves the practice absorbing the full procedure cost when Medicare denies.<\/li>\r\n
  • G2211 denied when billed with Modifier -25<\/strong> \u2014 a hard NCCI edit that practices using standard E\/M templates routinely trigger when a same-day procedure generates a -25 flag. The fix is a workflow-level separation: G2211 encounters should be identified at the scheduling level and routed to clean 99xxx billing without -25 modifier exposure.<\/li>\r\n<\/ul>\r\n

    The Hidden Revenue Threat: NCCI Edits and Bundling in DED Claims<\/h2>\r\n

    The Medicare National Correct Coding Initiative (NCCI) Procedure-to-Procedure (PTP) edits create bundling traps that catch DED claims regularly. Billing 83861 and 92285 on the same date requires documented separate medical necessity for each. Billing G2211 with a 92xxx eye code on the same claim triggers automatic rejection. These are not gray areas \u2014 they are hard edits that generate denials without clinical review.<\/p>\r\n

    Practices that standardize their dry eye disease billing CPT codes workflow around NCCI-aware claim scrubbing consistently outperform peers by 11\u201314 points on clean claim rate \u2014 a gap that translates directly to Days in AR and Net Collection Ratio.<\/p>\r\n

    Specialized optometry billing services<\/a> with active NCCI edit<\/a> monitoring prevent these bundling denials before claims leave the practice \u2014 a capability most general RCM vendors do not have built into their claim scrubbing infrastructure.<\/p>\r\n

    Documentation checklist: what every DED claim needs before submission<\/h2>\r\n

    Use this before submitting any dry eye disease billing CPT code to Medicare or major commercial payers:<\/p>\r\n

      \r\n
    • Documented symptom duration and prior conservative therapy (required for 83861 medical necessity)<\/li>\r\n
    • CLIA waiver number active and QW modifier applied (83861)<\/li>\r\n
    • Signed ABN on file prior to procedure date (0207T)<\/li>\r\n
    • E\/M code confirmed as 99xxx, not 92xxx, for G2211 encounters<\/li>\r\n
    • VSP lifetime plug count verified against patient history (68761)<\/li>\r\n
    • NCCI edit check completed for same-date code pairs (83861 + 92285; G2211 + 92xxx)<\/li>\r\n
    • Interpretation and report documented in chart for 92285<\/li>\r\n<\/ul>\r\n

      The 92xxx vs. 99xxx Decision: Where Most Practices Lose G2211 Revenue?<\/h2>\r\n

      The single most common dry eye disease billing CPT code decision that costs practices recurring revenue is defaulting to 92012 or 92014 for every DED follow-up. While 92012 (intermediate eye exam) is appropriate for many encounters, it blocks G2211.<\/p>\r\n

      For chronic DED patients where you serve as their longitudinal care coordinator \u2014 managing osmolarity trends, plug performance, and MGD therapy \u2014 migrating eligible encounters to 99213 or 99214 with G2211 appended can generate $18\u2013$34 in additional reimbursement per encounter<\/strong>. Across a busy DED panel, that compounds into five-figure annual recovery with zero new patient volume required.<\/p>\r\n

      This level of encounter-level revenue optimization requires optometry billing services with specialty-specific coding<\/a> protocols, not generalist billing staff applying one-size-fits-all E\/M guidelines.<\/p>\r\n